Vir Biotechnology, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Vir Biotechnology has filed its definitive proxy statement for the 2026 Annual Meeting of Stockholders to be held on May 26, 2026.
NASDAQ
Vir Biotechnology has filed a definitive proxy statement with the SEC.
NASDAQ
Vir Biotechnology's proxy statement details director nominees, executive compensation, and corporate governance practices for the upcoming 2025 Annual Meeting of Stockholders.
NASDAQ
Vir Biotechnology details its strategic direction, executive compensation, and board nominees in preparation for the 2024 Annual Meeting of Stockholders.
NASDAQ
Vir Biotechnology has filed a definitive proxy statement with the SEC.
NASDAQ
DEF 14A: Vir Biotechnology Announces Annual Meeting of Stockholders, Director Nominations Highlighted
Vir Biotechnology's upcoming annual meeting will include the election of directors and an advisory vote on executive compensation.